Yissum Spin Off PlantArray places sensors on plants to monitor hundreds of them simultaniously.
Surveillance cameras were not enough to catch the Boston Marathon terrorists. The Israeli-based BriefCam firm “collapsed” an hour of video and focused on suspicious objects – and people. Briefcam, a Yissum spin-off company is a world success.
Prof. Yechezkel Barenholz, co-inventor of the Doxil drug talks of the long journey from lab to market and of his new "baby" start up- Lipocure.
Prof. Marta Weinstock-Rosin was born on the wrong side of a lot of settings: In Austria she was too Jewish, at the British Academy in the early '50s she was too much of a woman, in Israel she was considered too British and for Novartis, manufacturer of her blockbuster drug Exelon she was too Israeli.
Prof. Haim Rabinowitch tell Globes how his scientific research changed the balance of power in agricultural world markets
Investment to Support BriefCam's Global Marketing and Sales Expansion for Video Synopsis Technology
In parallel, Holmen, a leading manufacturer in the forest based sector, has entered into an investment and sub-licensing agreement with Melodea, by which Holmen has become one of the major shareholders in Melodea.
Yissum Technology Transfer Company of the Hebrew University of Jerusalemis raising $5 million to invest in agro biotechnology companies. Yissum has already closed a $5 million fund for investment in life sciences companies, and now plans to replicate the success.
Yissum Spin off RegeneCure announced today the successful results of a clinical study in pets using the company's regenerative membrane implant technology for the treatment of bone fractures. The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies. The product was also demonstrated to be safe in all of the study participants.
Drug developer Avraham Pharmaceuticals Ltd. has raised $5.7 million fromYissum Technology Transfer Company of the Hebrew University of Jerusalem.Technion Research and Development Foundation, Clal Biotechnology Industries Ltd. (TASE: CBI) and the Pontifax fund. Following the current investment round, Yissum and Integra Holdings, Yissum's biotech holdings company, will now hold 47% of the shares of Avraham Pharmaceuticals.
Israeli scientists introduce new varieties of the popular legume that retain high nutritional values and produce a better yield.
Hebrew University develops more nutritious chickpeas adapted to limited rainfall. Yissum, the university’s research and development company, has introduced new chickpea varieties that retain high nutritional values while showing improved synchronization between flowering and the rainy season, thereby increasing yield.
A serendipitous lab discovery led to a breakthrough vaccine for a fatal tick-borne disease. Now investors are sought to take it commercial
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine
The company today reported positive results of the clinical trial of its drug for the treatment of necrotizing soft tissue infections.
When Ovadia Lev, Professor of Environmental Chemistry and Health at The Hebrew University of Jerusalem, and his research team developed a new coating technology a few years ago, they thought it was an interesting outcome of their research in hydrogen peroxide solutions. However, they weren't sure what to do with it until they met a team of researchers looking for a simple way to synthesize new lithium-ion battery anode materials, such as graphene-tin oxide composites.
Tiltan Pharma is one of the portfolio companies of Integra Holdings, a biopharmaceutical holding company founded by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
The blind have long used other senses -- including touch -- to compensate for their visual impairment. But a new study finds that when images are conveyed as sound, even the congenitally blind can distinguish among objects and their brains respond as if they are seeing.
Integra Holdings closes U.S. $ 7.0 million private financing
